Welcome to our available technologies page. Here you will find information on how to partner with BCM Ventures on packaged technologies that are available for licensing.
Featured Technology Package: Novel Small Molecule Activators and Inhibitors Offer Promising Therapy Potential in Cardiac and Cancer Indications
The steroid receptor coactivator-3 (SRC-3) is a protein that is required for normal growth in animal cells. Upregulating and downregulating the production of this protein with small molecules can have different effects throughout the body. SRC-3 has been implicated in several diseases such as cancer, metabolic disorders, HIV, neurodegenerative disorders, heart disease, and/or inflammatory diseases.
Researchers at Baylor College of Medicine have developed a novel small molecule activator as a potential therapeutic for restoration of cardiac tissue after a heart attack. As well as a novel small molecule indicator that slows tumor progression in certain types of cancer, including pancreatic and breast cancers.
Download the executive summary which provides an overview and market analysis for these two molecules.
Novel Small Molecule Activator Promotes Cardiac Protection and Repair
Key indication: heart failure
Potent, selective, small molecule activators of steroid receptor co-activators (SRC) can be developed into potential therapeutics for preservation, healing, and restoration of cardiac tissue after a heart attack.
Our proprietary MCB-613 compound is simpler to manufacture and shown improved outcomes post heart attack in mouse models. Competitive advantages include:
- Low toxicity in mouse cells and whole animal
- Compound ideally suited for oral administration
- Encourages tissue regeneration through microvasculature growth
Download PDF for additional details, including market analysis, value proposition, inventors and helpful links.
Novel Small Molecule Inhibitors for Use in Multiple Cancers
Key indications: breast and pancreatic cancers
Potent, selective, small molecule inhibitors of steroid receptor co-activators (SRC) can be developed into potential therapeutics for different types of cancers.
Our proprietary SI-12 compound is simpler and less costly to manufacture, distribute, store, and administer to patients. Competitive advantages include:
- Selectively toxic to cancer cells
- Efficacy in multiple in vivo cancer models
- Targeted approach of inhibiting SRC than chemotherapy
Download PDF for in-depth details, including market analysis, value proposition, inventors and helpful links.